Orexigen� Therapeutics, Inc. (�Orexigen�, �we�, �our� and �us�) is a
biopharmaceutical company focused on the development of pharmaceutical product
candidates for the treatment of obesity. Our product candidates are NB32
(formerly referred to as Contrave�), which has completed Phase III clinical
trials and which is currently being studied in a cardiovascular outcomes trial,
and Empatic�, which has completed Phase II clinical trials. Each of these
product candidates is a combination of generic drug components, each of which
has already received regulatory approval for other indications and been
commercialized in the United States and in a majority of the member countries of
the European Union. NB32 is a combination of two well-established drugs,
bupropion and naltrexone, each in a sustained release, or SR, formulation.
Bupropion is a widely prescribed antidepressant and smoking cessation
medication; naltrexone is a treatment for alcohol and opioid addiction.